Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Department of Ophthalmology, Kobe City Eye Hospital, Kobe, Hyogo, Japan.
PLoS One. 2023 May 2;18(5):e0284979. doi: 10.1371/journal.pone.0284979. eCollection 2023.
PURPOSE: To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV). METHODS: In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT. RESULTS: A significant intergroup difference was noted in terms of age (P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P < 0.01). CONCLUSIONS: A htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods.
目的:比较半量光动力疗法(htPDT)治疗慢性中心性浆液性脉络膜视网膜病变(cCSC)合并和不合并脉络膜新生血管(CNV)的两年疗效。
方法:在这项回顾性研究中,我们纳入了 88 例 88 只眼的 cCSC 患者,这些患者均接受了 htPDT 治疗,随访时间超过 24 个月。在 htPDT 治疗前,患者被分为合并 CNV(21 只眼)和不合并 CNV(67 只眼)两组。在 PDT 治疗前和治疗后 1、3、6、12 和 24 个月,评估最佳矫正视力(BCVA)、中心视网膜厚度(CRT)、中心凹下脉络膜厚度(SCT)和视网膜下液(SRF)的存在情况。
结果:在年龄方面,两组间存在显著的组间差异(P = 0.038)。在不合并 CNV 的眼中,BCVA 和 SCT 在所有时间点均有显著改善,但在合并 CNV 的眼中仅在 24 个月时有改善。两组 CRT 在所有时间点均显著降低。在所有时间点,两组间 BCVA、SCT 和 CRT 均无显著组间差异。两组间复发性和持续性 SRF 的发生率存在显著差异(无 CNV 组为 22.4%(22/99),有 CNV 组为 52.4%(11/21),P = 0.013;无 CNV 组为 26.9%(26/97),有 CNV 组为 57.1%(12/21),P = 0.017)。CNV 的存在与初始 PDT 后 SRF 的复发和持续性显著相关(P = 0.007 和 0.028)。Logistic 回归分析显示,初始 PDT 后 24 个月时的 BCVA 与基线 BCVA 显著相关(P < 0.01),而不是 CNV 的存在。
结论:对于 cCSC 患者,与不合并 CNV 的患者相比,CNV 的存在与 htPDT 后 SRF 的复发和持续性降低有关。在 24 个月的随访期间,CNV 眼可能需要额外的治疗。
Graefes Arch Clin Exp Ophthalmol. 2018-8
Photodiagnosis Photodyn Ther. 2021-3
Graefes Arch Clin Exp Ophthalmol. 2022-7